In order to elucidate the actionable therapeutic targets in BCR-ABL1+ leukemia, we next screened HSP90α/β-KO (K562) models on the ex vivo high throughput drug screening platform, consisting of conventional chemotherapeutics and targeted inhibitors (Supplemental Table 2). This evidence concerns the gene HSP90AA1 and leukemia.